Neuroendocrine Carcinoma
Conditions
Keywords
ORR, OS, PFS, safety
Brief summary
Currently, there is no standard second line treatment for patients with neuroendocrine carcinoma. Irinotecan monotherapy or combination regimen has shown promising in previous study. The study was designed to confirm thet FOLFIRI regimen can be used as a second-line regimen for patients with advanced or metastatic neuroendocrine carcinoma who have progressed after first-line chemotherapy with platinum based regimen.
Interventions
DRUGFOLFIRI Protocol
Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
Sponsors
Peking University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. sign written informed consent form 2. age ≥ 18 years 3. pathologically confirmed poorly-differentiated neuroendocrine carcinoma, G3(Ki67\>20%); 4. No prior antitumor treatment with irinotecan, progress after first line chemotherapy with platinum-based regimen. For recurrent patients after radical surgery, platinum-based adjuvant chemotherapy should beyond 6 months prior to randomization; 5. At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan \>=20mm, spiral CT scan \>=10mm, no prior radiation to measurable lesions); 6. Screening laboratory values must meet the following criteria (within past 7 days): hemoglobin ≥ 9.0 g/dL; neutrophils ≥ 1500 cells/ μL; platelets ≥ 100 x 10\^3/ μL; total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum creatinine ≤1╳ULN; 7. KPS ≥ 70; 8. Predicted survival \>=3 months; 9. Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women; 10. Sexually active males or females willing to practice contraception during the study until 30 days after end of study.
Exclusion criteria
1. Hypersensitivity to IRI,5-HT3 receptor antagonists; 2. Prior antitumor therapy (including corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment; 3. Received surgery within past 4 weeks, or have not recovered from surgery; 4. Severe diarrhea; 5. Concurrent severe infection； 6. Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including severe liver disease (active hepatitis, cirrhosis), uncontrolled diabetes or hypertension, or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm); 7. Prior long term steroid therapy (excluding short term steroid treatment which is completed prior to \> 2 weeks of study enrollment)； 8. Meningeal carcinomatosis; 9. Patients with central nervous system(CNS) disorder or peripheral nervous system disorder or psychiatric disease； 10. Known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, or congestive heart failure, or cardiac infarction within 6 months prior to study enrollment, or cardiac insufficiency； 11. Pregnant or nursing, or sexually active males or females refuse to practice contraception during the study until 30 days after end of study; 12. History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible； 13. Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons； 14. Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) | From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | CT/MRI will be performed every 2 cycles of treatment for efficacy evaluation by RECIST 1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | baseline, every 8 weeks up to 1 year after last patient first treatment | Progression-free survival is defined as the time from the date of first dose to the date of the first documented radiological progression or death due to any cause |
| Overall survival | baseline, every 8 weeks up to 1 year after last patient first treatment | Overall survival is defined as the time from date of start of treatment to date of death due to any cause |
| Incidence of Treatment-related Adverse Events （Safety and Tolerability） | From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Countries
China
Contacts
Primary ContactLin Shen
Outcome results
None listed